Jun Ishigooka

2.5k total citations
123 papers, 1.6k citations indexed

About

Jun Ishigooka is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Jun Ishigooka has authored 123 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Psychiatry and Mental health, 24 papers in Pharmacology and 21 papers in Experimental and Cognitive Psychology. Recurrent topics in Jun Ishigooka's work include Schizophrenia research and treatment (35 papers), Bipolar Disorder and Treatment (28 papers) and Treatment of Major Depression (22 papers). Jun Ishigooka is often cited by papers focused on Schizophrenia research and treatment (35 papers), Bipolar Disorder and Treatment (28 papers) and Treatment of Major Depression (22 papers). Jun Ishigooka collaborates with scholars based in Japan, United States and Malaysia. Jun Ishigooka's co-authors include Katsuji Nishimura, Hiroko Sugawara, Yoshihiro Tadori, Tadafumi Kato, Kaoru Sakamoto, Ken Inada, Kazuya Iwamoto, Miki Bundo, Teruhiko Higuchi and Junko Ueda and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biological Psychiatry and Journal of Affective Disorders.

In The Last Decade

Jun Ishigooka

120 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jun Ishigooka Japan 24 757 291 241 223 215 123 1.6k
Akihito Suzuki Japan 25 900 1.2× 313 1.1× 257 1.1× 184 0.8× 204 0.9× 156 2.2k
Marina Šagud Croatia 27 664 0.9× 278 1.0× 229 1.0× 276 1.2× 167 0.8× 111 2.0k
Jingping Zhao China 18 749 1.0× 195 0.7× 236 1.0× 239 1.1× 223 1.0× 65 1.7k
Jacob S. Ballon United States 16 753 1.0× 102 0.4× 254 1.1× 266 1.2× 217 1.0× 39 1.6k
A. Klimke Germany 22 709 0.9× 247 0.8× 174 0.7× 416 1.9× 196 0.9× 79 1.7k
Olli Kampman Finland 28 975 1.3× 380 1.3× 278 1.2× 182 0.8× 199 0.9× 112 2.1k
A.J.M. Loonen Netherlands 26 916 1.2× 251 0.9× 369 1.5× 289 1.3× 150 0.7× 161 2.4k
Ion Anghelescu Germany 21 557 0.7× 360 1.2× 233 1.0× 235 1.1× 225 1.0× 54 1.6k
Yuya Mizuno Japan 18 911 1.2× 192 0.7× 196 0.8× 149 0.7× 118 0.5× 35 1.7k
Marc Cantillon United States 20 558 0.7× 340 1.2× 138 0.6× 152 0.7× 221 1.0× 53 1.5k

Countries citing papers authored by Jun Ishigooka

Since Specialization
Citations

This map shows the geographic impact of Jun Ishigooka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Ishigooka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Ishigooka more than expected).

Fields of papers citing papers by Jun Ishigooka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Ishigooka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Ishigooka. The network helps show where Jun Ishigooka may publish in the future.

Co-authorship network of co-authors of Jun Ishigooka

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Ishigooka. A scholar is included among the top collaborators of Jun Ishigooka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Ishigooka. Jun Ishigooka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suzuki, Eriko, et al.. (2024). Association between TNF-α & IL-6 level changes and remission from depression with duloxetine treatment. International Journal of Neuroscience. 136(1). 1–6. 2 indexed citations
2.
Saito, Takuya, et al.. (2022). Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology. 32(1). 12–23. 8 indexed citations
3.
Iyo, Masaomi, Jun Ishigooka, Masatoshi Nakamura, et al.. (2021). Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatric Disease and Treatment. Volume 17. 2683–2695. 9 indexed citations
4.
Ishigooka, Jun, et al.. (2021). Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study. Human Psychopharmacology Clinical and Experimental. 36(4). e2777–e2777. 9 indexed citations
5.
Saito, Takuya, et al.. (2021). Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study. Journal of Child and Adolescent Psychopharmacology. 32(1). 24–35. 5 indexed citations
6.
Higuchi, Teruhiko, et al.. (2021). Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study. International Journal of Bipolar Disorders. 9(1). 25–25. 7 indexed citations
7.
Kato, Tadafumi, et al.. (2020). Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and Clinical Neurosciences. 74(12). 635–644. 28 indexed citations
8.
Takahashi, Hitoshi, et al.. (2020). Ziprasidone, a second-generation antipsychotic, affects core clock gene mRNA expression in mice. Journal of Pharmacological Sciences. 144(1). 57–59. 1 indexed citations
9.
Ishigooka, Jun, et al.. (2017). Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia. The Journal of Clinical Pharmacology. 58(1). 74–80. 24 indexed citations
10.
Muraoka, Hiroyuki, et al.. (2016). Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol. European Journal of Pharmacology. 781. 148–156. 13 indexed citations
11.
12.
Takahashi, Hitoshi, Keizo Yoshida, Hisashi Higuchi, et al.. (2014). Bcl1 Polymorphism of the Glucocorticoid Receptor Gene and Treatment Response to Milnacipran and Fluvoxamine in Japanese Patients with Depression. Neuropsychobiology. 70(3). 173–180. 5 indexed citations
13.
Ishigooka, Jun, et al.. (2014). Interpretation for scales of measurement linking with abstract algebra. PubMed. 4(1). 9–9. 2 indexed citations
14.
Ishigooka, Jun, Jun Nakamura, Yasuo Fujii, et al.. (2014). Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophrenia Research. 161(2-3). 421–428. 59 indexed citations
15.
Kobayashi, Sayaka, Katsuji Nishimura, Tsuyoshi Suzuki, Tsuyoshi Shiga, & Jun Ishigooka. (2013). Post‐traumatic stress disorder and its risk factors in Japanese patients living with implantable cardioverter defibrillators: A preliminary examination. SHILAP Revista de lepidopterología. 30(2). 105–110. 2 indexed citations
16.
Inoue, Yuichi, Tetsuo Shimizu, Koichi Hirata, et al.. (2013). Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Medicine. 14(11). 1085–1091. 18 indexed citations
17.
Sugawara, Hiroko, Miki Bundo, Jun Ishigooka, Kazuya Iwamoto, & Tadafumi Kato. (2012). Epigenetic Regulation of Serotonin Transporter in Psychiatric Disorders. Journal of genetics and genomics. 40(7). 325–329. 14 indexed citations
18.
Sugawara, Hiroko, et al.. (2010). Predictors of efficacy in lithium augmentation for treatment-resistant depression. Journal of Affective Disorders. 125(1-3). 165–168. 23 indexed citations
19.
Sakamoto, Kaoru, et al.. (2008). Incidence and predictors of activation syndrome induced by antidepressants. Depression and Anxiety. 25(12). 1014–1019. 37 indexed citations
20.
Ishigooka, Jun, et al.. (1996). Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.. PubMed. 16(1). 25–31. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akihito Suzuki Breakdown of academic impact, for papers by Marina Šagud Breakdown of academic impact, for papers by Jingping Zhao Breakdown of academic impact, for papers by Jacob S. Ballon Breakdown of academic impact, for papers by A. Klimke Breakdown of academic impact, for papers by Olli Kampman Breakdown of academic impact, for papers by A.J.M. Loonen Breakdown of academic impact, for papers by Ion Anghelescu Breakdown of academic impact, for papers by Yuya Mizuno Breakdown of academic impact, for papers by Marc Cantillon
Rankless by CCL
2026